Navigation Links
Wyeth Holds Annual Meeting of Stockholders
Date:4/24/2008

In 2007, our Company again delivered solid financial performance, with worldwide net revenue increasing 10%. Effective cost management added to the bottom line as pro forma diluted earnings per share increased 12%." He attributed this performance to Wyeth's position as a leading biotechnology company, the strength of its global business and growth across all three of the Company's core businesses in 2007 - pharmaceuticals, consumer healthcare products and animal health products. Also, Wyeth's pharmaceuticals business, for the first time in the Company's history, achieved more than $1 billion in full-year net sales in each of seven major product franchises: Effexor(R), the Premarin(R) family, Enbrel(R), Prevnar(R), Protonix(R), Zosyn(R) and Wyeth Nutritionals, demonstrating the breadth and depth of Wyeth's product portfolio.

In 2007, Wyeth received both U.S. and European approvals for Torisel(R), the first targeted therapy with a proven overall survival benefit in patients with advanced renal cancer. The Company also received U.S. marketing clearance for Lybrel(R), a low-dose combination contraceptive.

Mr. Poussot noted that, within the first four months of 2008, Wyeth has received U.S. Food and Drug Administration approval for two therapies that bring unique benefits to patients. Pristiq(TM) was cleared for use in major depressive disorder, providing patients with efficacy at a once-daily dose and without the need for titration. Xyntha(TM), a recombinant factor VIII product for patients with hemophilia A, was approved for the control and prevention of bleeding episodes and surgical prophylaxis. In addition, Relistor(TM) in a subcutaneous form was approved in Canada for the treatment of opioid-induced constipation in patients with advanced illness receiving palliative care.

Also during today's meeting, Emilio Emini, Ph.D., Executive Vice President, Vaccine Research and Development at Wyeth Pharmaceuticals, and Jim Connolly, Executive Vice Preside
'/>"/>

SOURCE Wyeth
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Wyeth and Nycomed Announce Court Denial of Preliminary Injunction
2. Wyeths Pearl River, N.Y. Facility Celebrates 100 Years of Achievements in Health care
3. Wyeth Announces Election of Bernard Poussot as CEO of Company Effective January 1, 2008
4. Wyeth Announces the Election of Robert M. Amen to Its Board of Directors
5. Wyeth Comments on PREVNAR and Trends in Pneumococcal Disease
6. Wyeth to Appeal Nevada Hormone Therapy Trial Verdict
7. Wyeth Reports Earnings Results for the 2007 Third Quarter and First Nine Months
8. Wyeth Consumer Healthcare Initiates Voluntary Recall and Replacement Program for Several Robitussin Products and Childrens Dimetapp Cold & Chest Congestion
9. Wyeth Consumer Healthcare Announces the Availability of Centrum Cardio and New Formula Centrum Products
10. Wyeth to Present at the Credit Suisse First Boston Healthcare Conference
11. Wyeth Receives FDA Approval of Protonix for Delayed-Release Oral Suspension
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/3/2015)... ... September 03, 2015 , ... ... treatment for adults and adolescents struggling with anorexia, bulimia, binge eating disorder ... medical treatment team. As a Staff Psychiatrist, Dr. Calinoiu collaborates closely with ...
(Date:9/3/2015)... ... ... According to an Oncology Nurse Advisor article published on August ... cancer (oral cancer) to be successfully diagnosed and treated for relapses of the disease. ... have a high rate of success in treatment and elimination of the disease; however, ...
(Date:9/3/2015)... ... September 03, 2015 , ... Atlantic Information Services, Inc. ... Pharmacy Benefit Strategies for a Rapidly Changing Marketplace.” In this Sept. 16 program, ... will discuss how plan sponsors are adopting bold, innovative strategies to control soaring ...
(Date:9/3/2015)... ... September 03, 2015 , ... ... efficacy endpoint data collection, cloud analytics and workflow solutions today announced the ... Lisbon, Portugal, September 22-24, 2015. The esteemed faculty of worldwide pharmaceutical and ...
(Date:9/3/2015)... ... , ... A scar is an unavoidable result of incision or injury to the skin. Unsightly ... heal itself. The appearance of a scar is dependent on many factors – the size ... ”Many scars fade to near invisibility on their own over a period of months,” says ...
Breaking Medicine News(10 mins):Health News:Ileana Calinoiu, MD Joins Eating Recovery Center of Washington Medical Treatment Team 2Health News:Ileana Calinoiu, MD Joins Eating Recovery Center of Washington Medical Treatment Team 3Health News:LA Periodontists Discuss Study on Post-Treatment Oral Rinses Used to Test Recurrence of Oral Cancers 2Health News:LA Periodontists Discuss Study on Post-Treatment Oral Rinses Used to Test Recurrence of Oral Cancers 3Health News:Speakers for Upcoming AIS Virtual Conference on Pharmacy Benefit Strategies Include Executives from CVS Health, Express Scripts 2Health News:ERT Announces Final Agenda, Faculty for European PRO / eCOA Congress 2Health News:ERT Announces Final Agenda, Faculty for European PRO / eCOA Congress 3Health News:Do I Have To Live With That Scar? 2Health News:Do I Have To Live With That Scar? 3Health News:Do I Have To Live With That Scar? 4
... Andy Stern Joins CA Governor, Assembly Speaker As,California ... SACRAMENTO, Calif., Dec. 17 Andy Stern,president of ... and the,nation, joined the Governor of California, the ... national figures to rally support for,landmark legislation that ...
... AIDS Healthcare,Foundation (AHF) today strongly criticized Ryan ... budget package drafted by Congress in order,to meet ... target for,next year. The fiscal year 2008 Labor-Health ... House today and is,expected to be introduced in ...
... MIDLOTHIAN, Va., Dec. 17 PARI Hydrate, a ... Food and Drug,Administration (FDA) and will be marketed ... Manufacturers, a leading,manufacturer of aerosol nebulizers and compressors, ... are heated and humidified with the,aim to reduce ...
... they were to get the disease, study found , , MONDAY, ... as sunlight may help prevent some lung cancers, researchers say. ... sun,s ultraviolet B (UVB) rays are associated with a higher ... that doesn,t mean that spending more time in the sun ...
... Dec. 17 The board of directors,of Eli Lilly and ... in its quarterly dividend. The board declared a dividend for ... common stock. This,raises the annual indicated rate to $1.88 per ... has increased the dividend payment., The dividend is payable ...
... Buy Health Insurance With No Limit,on Price or Promise ... Labor unions,hospitals and doctors, health insurers and the ... measure to extend,legislative term limits, as they sought and ... legislation, AB 1x, according,to an analysis released today by ...
Cached Medicine News:Health News:California Breakthrough a 'Pivotal Moment' in Fight to Transform Nation's Health Care System 2Health News:Ryan White Funding Proposal Demonstrates Neglect of US' Growing AIDS Epidemic, Says AHF 2Health News:Ryan White Funding Proposal Demonstrates Neglect of US' Growing AIDS Epidemic, Says AHF 3Health News:PARI Hydrate Receives FDA Clearance 2Health News: Sunlight Helps Put Lung Cancer in the Shade 2Health News: Sunlight Helps Put Lung Cancer in the Shade 3Health News:Labor & Medical Industry Give 56% of Prop 93 $$ to Win Concessions in Health Care Legislation 2Health News:Labor & Medical Industry Give 56% of Prop 93 $$ to Win Concessions in Health Care Legislation 3
(Date:9/3/2015)...  Four financial reasons to reduce pressure ulcers ... by Leaf Healthcare, Inc . According ... (AHRQ), pressure ulcers cost the US healthcare ... addition to direct treatment related costs, pressure ulcers ... impact hospital performance metrics. On top of the ...
(Date:9/3/2015)... 2015 Research and Markets ( http://www.researchandmarkets.com/research/4q3mv2/investigation ) ... on China Olmesartan Market, 2010-2019" report to their ... successfully developed by Sankyo Pharmaceuticals Co., Ltd and was ... was approved by FDA to enter the American market ... drug in the world after it succeeded in the ...
(Date:9/3/2015)... Sep. 03, 2015 Research ... of the "Investigation Report on China,s Bromhexine Market, ... air pollution worsens, the incidence of respiratory disease keeps ... drugs. Bromhexine, a semisynthetic derivative of vasicine, is a ... and asthma associated with viscid or excessive mucus. It ...
Breaking Medicine Technology:Four Financial Reasons to Reduce Pressure Ulcer Incidents: Leaf Healthcare Releases White Paper on Direct and Indirect Costs Associated with Pressure Ulcers 2Four Financial Reasons to Reduce Pressure Ulcer Incidents: Leaf Healthcare Releases White Paper on Direct and Indirect Costs Associated with Pressure Ulcers 3China Olmesartan Investigation Market Report 2010-2019 2China Bromhexine Market Report 2015-2019 2
... The OMEGA 180 features a wide range ... Small and Variable Pupil Control (U.S. Patent ... sizes down to 1.2mm. Heine's unique Diffuser ... making learning BIO easier, and simplifying difficult ...
... 2006 is a long-term Transtelephonic dual ... This device is the solution of ... and their correlation to the patient's ... provides 2 lead loop recording information ...
The latest addition to Aerotels Transtelephonic ECG product line, HeartOne™ is a unique miniaturized single-lead, 4-event recorder/transmitter designed for transmission on cellular (GSM) and an...
... For General Practitioners (GP'S) ... ECGs by phone to a ... 2.5 seconds per lead and ... as rhythm lead. Sequentially transmits ...
Medicine Products: